Nonhuman Primate Core

随着高效抗逆转录病毒疗法(HAART)的出现，在以下方面取得了重大进展 控制病毒复制和延长艾滋病毒感染者的无艾滋病生存期。然而， 目前的治疗方式不能有效地针对或消除潜伏的病毒库。因此，病毒 经常在停止治疗后反弹。严重的副作用和耐药性是常见的，因为 长期使用多种药物治疗的必要性。因此，抗艾滋病毒治疗的最终目标应该是 病毒学根除，即治愈艾滋病毒感染。到目前为止，根除病毒学的可行性只有 一名HIV感染患者接受了来自中国的异基因造血细胞移植(HCT)。 CCR5delta32纯合子供者。尽管这是一项重要的概念验证研究，但 使用人类白细胞抗原相合的CCR5delta32纯合子供者作为一般的治疗方法还很遥远。这个 该U19应用程序的总体目标是探索在主机和 以前病毒DNA为靶点并消除潜在的HIV病毒蓄积者。此核心的目标是提供全面的 支持非人类灵长类动物模型的概念验证研究。这一目标将通过 执行以下具体目标：(1)。提供动物资源，畜牧业，以及 研究非人灵长类中慢病毒感染所需的生物安全控制设施 模型；(2)为实施非人灵长类研究提供技术和临床支持 U19应用程序中的协议；(3)为监测提供实验室专业知识和分析支持 (4)为以下行为提供科学和行政监督： 非人灵长类研究。这一核心将与这款U19的所有项目和核心互动。

With the advent of highly active anti-retroviral therapy (HAART), significant progress has been achieved in the control of viral replication and prolongation of AIDS-free survival in HIV infected individuals. However, current therapeutic modalities do not effectively target or eliminate latent viral reservoirs. As a result, virus often rebounds after cessation of therapy. Significant side effects and drug-resistance are common due to the necessity for long-term multidrug therapy. An ultimate goal for anti-HIV therapy should therefore be virological eradication, i.e., to cure HIV infection. To date, the feasibility of virologic eradication has only been demonstrated in one HIV-infected patient given an allogeneic hematopoietic cell transplant (HCT) from a CCR5delta32 homozygous donor. Although this is an important proof-of-concept study, the likelihood of using HLA-matched and CCR5delta32 homozygous donor as a general therapeutic approach is remote. The overall objective of this U19 application is to explore strategies to introduce specific modifications in host and proviral DNA to target and eliminate latent HIV reservoir. The goal of this Core is to provide comprehensive support for the proof-of-concept studies in non-human primate models. This goal will be achieved through the execution of the following Specific Aims: (1). To provide animal resources, animal husbandry, and biosafety containment facilities necessary for the study of primate lentivirus infection in a non-human primate model; (2) To provide technical and clinical support for the implementation of non-human primate study protocols in this U19 application; (3) To provide laboratory expertise and analytical support for the monitoring of SHIV infection in macaques; and (4) To provide scientific and administrative oversight for the conduct of non-human primate studies. This Core will interact with all Projects and Cores of this U19.